Resolution by the board of directors not to
distribute dividends
Date of events
2022/03/21
To which item it meets
paragraph 14
Statement
1.Date of the board of directors resolution :2022/03/21
2.Year or quarter which dividends belong to:2021
3.Period which dividends belong to:2021/1/1~2021/12/31
4.Appropriations of earnings in cash dividends to shareholders
(NT$ per share):0
5.Cash distributed from legal reserve and capital surplus to shareholders
(NT$ per share):0
6.Total amount of cash distributed to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders
(NT$ per share):0
8.Stock distributed from legal reserve and capital surplus to shareholders
(NT$ per share):0
9.Total amount of stock distributed to shareholders (shares):0
10.Any other matters that need to be specified:0
11.Per value of common stock:NT$ 10
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 21 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 March 2022 11:37:05 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.